NEW ORLEANS ― Computer applications (apps) on electronic tablets such as iPads may offer a safe, effective, nonpharmacologic option for addressing agitation in dementia patients who have associated ...
Results from a Phase II, multi-center study found dronabinol, a synthetic version of the active ingredient in marijuana, reduces agitation in patients with Alzheimer's disease. San Antonio, Texas ...
ATLANTA — With funding for a new trial secured, electroconvulsive therapy (ECT) is gaining ground as a possible treatment for severe agitation and aggression in patients with Alzheimer's disease (AD).
A Saint Louis University researcher was instrumental in developing the first and only Food and Drug Administration (FDA) approved treatment for agitation associated with Alzheimer’s dementia. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results